Human Cell-based Drug Discovery Assets

Discovered, validated and profiled using diseased and normal human cells as the discovery platform technologies

What We Do
Cellular Therapy and Regeneration, microscope of cell, Embryonic

Discovering a better future

AeroNeph Therapeutics, Inc. has emerged from the humanized drug discovery approach of its parent company, DiscoveryBioMed, Inc., and is continuing to develop lead and hit-to-lead small molecules for specific human disease indications and for human taste marketplaces.

Who We Are

R&D Programs

AeroNeph specializes in developing cell-based discovery assets. Through our various research and development programs, our goal is to improve the treatment for human genetic kidney and respiratory diseases, diabetes, obesity complications and lupus.

View Programs


STING Inhibitor MJFF

AeroNeph Therapeutics, Inc. Nominates a Hit-to-Lead STING Inhibitor Small Molecule for In Vivo Studies Focused on Parkinson’s Disease and for Further Development in Autoinflammatory and Autoimmune Disease Indications In studies begun by DiscoveryBioMed, Inc. in collaboration with Nitor Therapeutics, Inc. (Birmingham, AL) and funded by a Phase 1 SBIR grant award, AeroNeph Therapeutics, Inc. (Birmingham, […]